Analysed REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) News Sources
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
15-12-2025
yahoo.com
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
05-01-2026
yahoo.com
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
22-04-2026
yahoo.com
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
27-04-2026
yahoo.com
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
30-04-2026
yahoo.com
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
02-06-2026
yahoo.com
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
08-06-2026
yahoo.com
What is the current price of REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ)?
The current price of REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) is $0.794.
REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) absolute price change since previous trading day?
The absolute price change of REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) since the previous trading day is $0.003.
REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) percentage price change since previous trading day?
The percentage price change of REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) since the previous trading day is 0.3793%.
What is the most recent average sentiment score for REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ)?
The most recent average sentiment score for REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ)?
The most recent sentiment for REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ) is .
SEC-8K** Filing Available For REDHILL BIOPHARMA LTD-SP ADR (RDHL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.